title: Addition of aliskiren to angiotensin II receptor blockers ameliorates renal tubular injury and reduces intima media thickness of carotid artery in patients with diabetic nephropathy.
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Nakamura
authors.forename: Eiichi
authors.initials: E
authors.lastname: Sato
authors.forename: Mayuko
authors.initials: M
authors.lastname: Amaha
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Kawagoe
authors.forename: Sayaka
authors.initials: S
authors.lastname: Maeda
authors.forename: Sho-ichi
authors.initials: S
authors.lastname: Yamagishi
mesh_terms: D000368:Aged; D000577:Amides / Q000008:administration & dosage*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D059168:Carotid Intima-Media Thickness; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005650:Fumarates / Q000008:administration & dosage*; D006801:Humans; D007684:Kidney Tubules / Q000187:drug effects*; D008297:Male; D008875:Middle Aged
chemical_list: D000577:Amides; D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D005650:Fumarates; C446481:aliskiren